GENTILLY, France--(BUSINESS WIRE)--THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance ...

THX Pharma and Biocodex have announced a strategic licensing agreement to support the development and commercialisation of treatments for three rare genetic diseases with high unmet medical needs.

KANSAS CITY, MO, UNITED STATES, January 27, 2026 /EINPresswire.com/ — Onyx, the leading healthcare interoperability platform provider and 2025 Best in KLAS ® for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Biocodex secures rights to Batten-1 and TX01 in agreement worth up to €173 million THX Pharma and Biocodex have entered a strategic licensing agreement covering three rare diseases, with Biocodex ...

Samsung Electronics America, along with the Georgia Theatre Company and its channel partner, GDC Technology America, have delivered an enhanced moviegoing experience at Trilith Cinemas in Fayetteville ...

Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including a €12 ...

Biocodex obtained an exclusive worldwide license for Batten-1 and an exclusive US/Canada license for TX01, while THX Pharma retains leadership of clinical development ...

GENTILLY, France, February 10, 2026--(BUSINESS WIRE)--THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.